Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy

Clin Immunol. 2020 Oct;219:108550. doi: 10.1016/j.clim.2020.108550. Epub 2020 Jul 31.
No abstract available

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Betacoronavirus / drug effects
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity
  • Biomarkers / blood
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / metabolism
  • Coronavirus Infections / virology
  • Cytokine Release Syndrome / drug therapy*
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / metabolism
  • Cytokine Release Syndrome / virology
  • Cytokines / antagonists & inhibitors
  • Cytokines / genetics
  • Cytokines / immunology
  • Drug Administration Schedule
  • Gene Expression Regulation
  • Glucocorticoids / therapeutic use*
  • Homeostasis / drug effects*
  • Homeostasis / immunology
  • Humans
  • Hydrocortisone / blood
  • Immunity, Innate / drug effects
  • Inflammation / prevention & control
  • NF-kappa B / genetics
  • NF-kappa B / immunology
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / metabolism
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Stress, Physiological
  • Treatment Outcome
  • Vitamins / blood

Substances

  • Anti-Inflammatory Agents
  • Biomarkers
  • Cytokines
  • Glucocorticoids
  • NF-kappa B
  • Vitamins
  • Hydrocortisone